Skip to content

Coagulation Parameters in IBD Patients

Coagulation Parameters in IBD Patients

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04115722
Enrollment
50
Registered
2019-10-04
Start date
2019-11-30
Completion date
2020-12-31
Last updated
2019-10-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coagulopathy

Brief summary

1. to assess the incidence of coagulation disorders in IBD patients in comparison with another normal controlled group 2. risk factors that contribute to development of thrombosis in IBD patients 3. to determine the effectiveness of prophlactive anticoagulant measures 4. to determine the association between disease activity and coagulation parameters

Detailed description

Inflammatory bowel disease is a group of disorders associated with chronic, recurrent, and immune system-mediated inflammation of The bowel mucosa . The reported global incidence and prevalence rates for ulcerative colitis vary between 1.2-20.3 and 6-246 per 100000 persons, respectively, and the corresponding figures for Crohns disease are 0.03-15.6 and 3.6-214 \[2 In a population based cohort study involving 1160 patients with ulcerative colitis, the complication-related mortality rate was 9.6% during follow-up period of 35 years, in another study, 221 patients with Crohns disease were followed up for 33 years, with an overall complication-related mortality rate of Of the extra-intestinal manifestations of inflammatory bowel disease (IBD), thromboembolic events represent a major cause of morbidity and mortality with a 3.6 times increased risk in comparison with the general population . Although clinical observations suggest an incidence rate between 1 and 8% for thromboembolic events in subjects with IBD, postmortem studies point out to a much higher occurrence rate around 41% . As a matter of fact, these and similar findings have led to an increased interest in the search for the association between IBD and hypercoagulable states as a potential cause of increased morbidity and mortality due to thromboembolic events in IBD . For instance, the existence of documentable prothrombotic abnormalities and a positive history for thromboembolic complications were demonstrated in at least one third of the subjects with IBD in a study by Solem et al Inflammation and coagulation are two crucial systems that are in balance and constantly influence each other. The impact of inflammation on coagulation has been confirmed by several experimental studies showing that inflammatory mechanism shift the hemostatic balance to favor the activation of coagulation which, in turn, can also sustain inflammation promoting a vicious circle between chronic inflammation and thrombosis

Interventions

OTHERIBD ACTIVIT

Effect of IBD disease and activity of disease on coagulation parameters

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years

Inclusion criteria

All patients of IBD more than 18 years

Exclusion criteria

-All IBD patients less than 18 years-all diseases that cause coagulation disorders all diseases that cause coagulation disorders ( liver diseases , collagen diseases, other auto immune disease

Design outcomes

Primary

MeasureTime frame
Percentage of IBD patients in activity with DVTWithin one year dollow up

Contacts

Primary ContactMohamed Ali mahmoud
mohamedali325a@gmail.com01008669215
Backup ContactMahmoud Ali mahmoud ashry
mahmoud.ashri@med.au.edu.eg01006901937

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026